A subsidiary of TransCelerate BioPharma Inc.
BioCelerate, a subsidiary of TransCelerate BioPharma Inc., focuses on the identification and development of pragmatic and tangible solutions to improve efficiencies in preclinical research, with the end goal of improving overall drug development efficiency to bring new medicines to patients faster. By actively collaborating with participating TransCelerate Member Companies and other industry stakeholders, BioCelerate leverages collective knowledge to tackle areas of common challenge and unmet need in the preclinical research space.
The six initial biopharmaceutical companies committed to launching BioCelerate include Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk and Shionogi & Co., Ltd.
BioCelerate is led by the Chief Executive Officer of TransCelerate, Dalvir Gill, PhD. For more on Dr. Gill, please see his bio on the TransCelerate leadership page.
BioCelerate is a subsidiary of TransCelerate BioPharma, and draws upon separate funding and support. In order to participate in BioCelerate it is necessary to be a Member Company of TransCelerate BioPharma, Inc. TransCelerate membership is available to biopharmaceutical research and development organizations who engage in innovative discovery, development and manufacturing of new drugs.
Information about membership and a membership application is available on the TransCelerate website.
BioCelerate initiatives are approved by a Governing Council comprised of representatives from participating BioCelerate Companies. Additional details on these initiatives will be released in 2017.
BioCelerate’s first initiative, Toxicology Data Sharing, is focused on enabling access to a broader cross-company set of toxicology data and is motivated in part by the Food and Drug Administration's (FDA) 2011 Strategic Plan for Regulatory Science, which includes objectives to modernize toxicology to enhance product safety.
The knowledge gathered through this Initiative will help with effective translation of nonclinical findings and attempt to close critical gaps that exist in understanding the relationship between patient response and preclinical toxicology findings.
Please direct inquiries regarding conferences, media requests, membership or any other questions to our email address at firstname.lastname@example.org.
BioCelerate executive offices are located at:
TransCelerate BioPharma, Inc.100 Four Falls Corporate Center, Suite 6551001 Conshohocken State RoadConshohocken, PA 19428